Dataset Information

Integrated Transcriptomic and Glycomic Profiling of Glioma Stem Cell Xenografts.

ABSTRACT: Bone marrow-derived human mesenchymal stem cells (BM-hMSCs) have the innate ability to migrate or home toward and engraft in tumors such as glioblastoma (GBM). Because of this unique property of BM-hMSCs, we have explored their use for cell-mediated therapeutic delivery for the advancement of GBM treatment. Extravasation, the process by which blood-borne cells—such as BM-hMSCs—enter the tissue, is a highly complex process but is heavily dependent upon glycosylation for glycan-glycan and glycan-protein adhesion between the cell and endothelium. However, in a translationally significant preclinical glioma stem cell xenograft (GSCX) model of GBM, BM-hMSCs demonstrate unequal tropism toward these tumors. We hypothesized that there may be differences in the glycan compositions between the GSCXs that elicit homing ("attractors") and those that do not ("non-attractors") that facilitate or impede the engraftment of BM-hMSCs in the tumor. In this study, glycotranscriptomic analysis revealed significant heterogeneity within the attractor phenotype and the enrichment of high mannose type N-glycan biosynthesis in the non-attractor phenotype. Orthogonal validation with topical PNGase F deglycosylation on the tumor regions of xenograft tissue, followed by nLC-ESI-MS, confirmed the presence of increased high mannose type N-glycans in the non-attractors. Additional evidence provided by our glycomic study revealed the prevalence of terminal sialic acid-containing N-glycans in non-attractors and terminal galactose and N-acetyl-glucosamine N-glycans in attractors. Our results provide the first evidence for differential glycomic profiles in attractor and non-attractor GSCXs and extend the scope of molecular determinates in BM-hMSC homing to glioma.

SUBMITTER: Wildburger NC

PROVIDER: S-EPMC4917366 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Integrated Transcriptomic and Glycomic Profiling of Glioma Stem Cell Xenografts.

Wildburger Norelle C NC Zhou Shiyue S Zacharias Lauren G LG Kroes Roger A RA Moskal Joseph R JR Schmidt Mary M Mirzaei Parvin P Gumin Joy J Lang Frederick F FF Mechref Yehia Y Nilsson Carol L CL

Journal of proteome research 20150804 9

Bone marrow-derived human mesenchymal stem cells (BM-hMSCs) have the innate ability to migrate or home toward and engraft in tumors such as glioblastoma (GBM). Because of this unique property of BM-hMSCs, we have explored their use for cell-mediated therapeutic delivery for the advancement of GBM treatment. Extravasation, the process by which blood-borne cells—such as BM-hMSCs—enter the tissue, is a highly complex process but is heavily dependent upon glycosylation for glycan-glycan and glycan-p ...[more]

PMID: 26185906

Similar Datasets

Project description:One sub-project within the global Chromosome 19 Consortium, part of the Chromosome-Centric Human Proteome Project, is to define chromosome 19 gene and protein expression in glioma-derived cancer stem cells (GSCs). Chromosome 19 is notoriously linked to glioma by 1p/19q co-deletions and clinical tests are established to detect that specific aberration. GSCs are tumor-initiating cells and are hypothesized to provide a repository of cells in tumors that can self-replicate and be refractory to radiation and chemotherapeutic agents developed for the treatment of tumors. In this pilot study, we performed RNA-Seq, label-free quantitative protein measurements in six GSC lines, and targeted transcriptomic analysis using a chromosome 19 specific microarray in an additional 6 GSC lines. Here, we present insights into differences in GSC gene and protein expression, including the identification of proteins listed as having no or low evidence at the protein level (such as small nuclear ribonucleoprotein G-like protein, RUXGL_HUMAN), as correlated to chromosome 19 and GSC subtype. Furthermore, the upregulation of proteins downstream of adenovirus-associated viral integration site 1 (AAVS1) in GSC11 in response to oncolytic adenovirus treatment was demonstrated. Taken together, our results may indicate new roles for chromosome 19, beyond the 1p/19q co-deletion, in the future of personalized medicine for glioma patients. Data analysis: MS files (.raw) were imported into Progenesis LC-MS (version 18.214.1528, Nonlinear Dynamics) for m/z and retention time alignment. The top 5 spectra for each feature were exported (charge deconvolution, top 1000 peaks) as a combined .mgf file for database searching in PEAKS (version 6, Bioinformatics Solutions Inc., Waterloo, ON) against the UniprotKB/Swissprot-Human database (July 2013 version, 20,264 proteins), appended with the cRAP contaminant database. PEAKS DB and Mascot (version 2.3.02, Matrix Science) searches were performed with a parent ion tolerance of 10 ppm, fragment ion tolerance of 0.025 Da, fixed carbamidomethyl cysteine, and variable modifications of oxidation (M), phosphorylation (STY), and deamidation (NQ). Trypsin was specified as the enzyme, allowing for 2 missed cleavages and a maximum of 3 PTMs per peptide. An additional search for unexpected modifications was performed with the entire Unimod database. Finally, homology searching was performed using the SPIDER algorithm to identify peptides resulting from nonspecific cleavages or amino acid substitutions. Mascot and PEAKS SPIDER searches were combined (inChorus), using a 1% false discovery rate cutoff for both search engines. The resulting peptide-spectrum matches (95% peptide probability) were imported into Progenesis LC-MS. Conflict resolution was performed manually to ensure that a single peptide sequence was assigned to each feature by removing lower scoring peptides. The resulting normalized peptide intensity data were exported, and the peptide list was filtered to remove non-unique peptides, methionine-containing peptides, and all modified peptides except cysteine carbamidomethylation. For quantification, the filtered list of peptide intensities was imported into DanteR (version 0.1.1), and intensities for peptides of the same sequence were combined to form a single entry. The resulting peptide intensities were log2 transformed and combined to protein abundances (RRollup) using the default settings, excluding one-hit wonders (50% minimum presence of at least one peptide, minimum dataset presence 3, p-value cutoff of 0.05 for Grubbs’ test, minimum of 5 peptides for Grubbs’ test). The resulting proteins were quantified by 1-way ANOVA relative to M37; p-value adjustment for multiple testing was performed according to Benjamini and Hochberg.

Project description:Tumor heterogeneity of high-grade glioma (HGG) is recognized by four clinically relevant subtypes based on core gene signatures. However, molecular signaling in glioma stem cells (GSCs) in individual HGG subtypes is poorly characterized. Previously we identified and characterized two mutually exclusive GSC subtypes with distinct activated signaling pathways and biological phenotypes. One GSC subtype presented with a gene signature resembling Proneural (PN) HGG, whereas the other was similar to Mesenchymal (Mes) HGG. Classical HGG-derived GSCs were sub-classified as either one of these two subtypes. Differential mRNA expression analysis of PN and Mes GSCs identified 5,796 differentially expressed genes, revealing a pronounced correlation with the corresponding PN or Mes HGGs. Mes GSCs displayed more aggressive phenotypes in vitro and as intracranial xenografts in mice. Further, Mes GSCs were markedly resistant to radiation compared with PN GSCs. Expression of ALDH1A3 - one of the most up-regulated Mes representative genes and a universal cancer stem cell marker in non-brain cancers - was associated with self-renewal and a multi-potent stem cell population in Mes but not PN samples. Moreover, inhibition of ALDH1A3 attenuated the growth of Mes but not PN GSCs in vitro. Lastly, radiation treatment of PN GSCs up-regulated Mes-associated markers and down-regulated PN-associated markers, whereas inhibition of ALDH1A3 attenuated an irradiation-induced gain of Mes identity in PN GSCs in vitro. Taken together, our data suggest that two subtypes of GSCs, harboring distinct metabolic signaling pathways, represent intertumoral glioma heterogeneity and highlight previously unidentified roles of ALDH1A3-associated signaling that promotes aberrant proliferation of Mes HGGs and GSCs. Inhibition of ALDH1A3-mediated pathways therefore might provide a promising therapeutic approach for a subset of HGGs with the Mes signature. Here, we describe the gene expression analysis, including pre-processing methods for the data published by Mao and colleagues in PNAS [1], integration of microarray data from this study with The Cancer Genome Atlas (TCGA) glioblastoma data and also with another published study.

Dataset Information

Integrated Transcriptomic and Glycomic Profiling of Glioma Stem Cell Xenografts.

Publications

Integrated Transcriptomic and Glycomic Profiling of Glioma Stem Cell Xenografts.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets